Enveric Completes Manufacturing Of Its Psilocin Prodrug To Supply Drug Material For Completion Of Preclinical Program
Portfolio Pulse from Vuk Zdinjak
Enveric Biosciences (NASDAQ:ENVB) has completed the manufacturing of its psilocin prodrug, EB-373, enabling the completion of preclinical work. The company will now commence remaining GLP studies to provide data required for human trials. The manufacturing process resulted in a high purity product, allowing Enveric and its partners to handle and ship EB-373 without restrictions for controlled substances. The company expects to complete all remaining preclinical studies required for Human Research Ethics Committee submission in Australia by the end of 2023.
August 21, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has completed the manufacturing of its psilocin prodrug, EB-373, which will enable the completion of preclinical work. The high purity product can be handled and shipped without restrictions, potentially saving time and costs in future clinical trials.
The completion of the manufacturing process for EB-373 is a significant milestone for Enveric Biosciences, as it allows the company to proceed with the remaining GLP studies required for human trials. The high purity of the product also eliminates the need for restrictive handling and shipping requirements, which could result in cost and time savings for the company. This news is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100